文献速递神经肿瘤

多数临床抗EGFR抗体不能同时中和胶质瘤中wtEGFR与EGFRvIII激活

Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma.
PubMed 文献 · Neuro Oncol · 2019-01-01

本研究在患者来源的胶质瘤球(内源性表达EGFRvIII)中重新评估临床抗EGFR抗体的活性。结果显示,靶向EGFR结构域III的西妥昔单抗、奈妥木单抗、尼妥珠单抗和马妥昔单抗均不能中和EGFRvIII激活;ch806仅中和EGFRvIII而不中和wtEGFR;帕尼单抗是唯一同时中和EGFRvIII和wtEGFR的抗体,并表现出更优的体外和体内抗肿瘤活性。

要点

  • 多数靶向EGFR结构域III的临床抗体不能中和EGFRvIII激活,构成胶质瘤耐药机制。
  • 帕尼单抗是唯一同时中和EGFRvIII和wtEGFR的抗体,并降低p-S6信号。
  • 帕尼单抗通过独特亲和力稳定交联EGFRvIII以阻止其激活,支持进一步临床测试。

核心结论

  • 多数靶向EGFR结构域III的抗体不能中和EGFRvIII,是胶质瘤中先前未知的主要耐药机制。
  • 帕尼单抗同时中和EGFRvIII和wtEGFR,体外和体内抗肿瘤活性优于其他测试抗体。

研究设计与样本

  • 使用内源性表达EGFRvIII的患者来源胶质瘤球进行体外增殖实验和颅内原位移植瘤实验。
  • 通过免疫沉淀和蛋白质印迹分析受体激活状态、抗体结合、致癌信号及作用机制,免疫荧光追踪抗体受体复合物。

主要发现

  • 西妥昔单抗、奈妥木单抗、尼妥珠单抗和马妥昔单抗未中和EGFRvIII激活。
  • ch806中和EGFRvIII但不中和wtEGFR激活。
  • 帕尼单抗是唯一同时中和EGFRvIII和wtEGFR的抗体,降低p-S6信号并展现更优体外和体内抗肿瘤活性。
  • 帕尼单抗诱导受体再循环而非降解,通过独特亲和力稳定交联EGFRvIII阻止其激活;ch806显著减少活性EGFRvIII二硫键二聚体。

临床怎么用

  • 在EGFRvIII分层胶质瘤中,帕尼单抗的支持进一步临床测试。
  • 靶向EGFR结构域III的抗体需评估对EGFRvIII的中和能力,避免耐药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although epidermal growth factor receptor (EGFR) and its truncated, autoactive mutant EGFR variant (v)III are bona fide drivers of tumorigenesis in some gliomas, therapeutic antibodies developed to neutralize this axis have not improved patient survival in a limited number of trials. Previous studies using cells transduced to exogenously express EGFRvIII may have compromised mechanistic studies of anti-EGFR therapeutics. Therefore, we re-assessed the activity of clinical EGFR antibodies in patient-derived gliomaspheres that endogenously express EGFRvIII. METHODS: The antitumor efficacy of antibodies was assessed using in vitro proliferation assays and intracranial orthografts. Receptor activation status, antibody engagement, oncogenic signaling, and mechanism of action after antibody treatment were analyzed by immunoprecipitation and western blotting. Tracking of antibody receptor complexes was conducted using immunofluorescence. RESULTS: The EGFR domain III-targeting antibodies cetuximab, necitumumab, nimotuzumab, and matuzumab did not neutralize EGFRvIII activation. Chimeric monoclonal antibody 806 (ch806) neutralized EGFRvIII, but not wild-type (wt)EGFR activation. Panitumumab was the only antibody that neutralized both EGFRvIII and wtEGFR, leading to reduction of p-S6 signaling and superior in vitro and in vivo antitumor activity. Mechanistically, panitumumab induced recycling of receptor but not degradation as previously described. Panitumumab, via its unique avidity, stably cross-linked EGFRvIII to prevent its activation, while ch806 induced a marked reduction in the active EGFRvIII disulphide-bonded dimer. CONCLUSIONS: We discovered a previously unknown major resistance mechanism in glioma in that most EGFR domain III-targeting antibodies do not neutralize EGFRvIII. The superior in vitro and in vivo antitumor activity of panitumumab supports further clinical testing of this antibody against EGFRvIII-stratified glioma.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Greenall SA, McKenzie M, Seminova E, et al. Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma. Neuro Oncol. 2019. PMID: 31002307. doi:10.1093/neuonc/noz073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。